NCT06257394 (VHR ALL) is a Phase 2 clinical trial of Dasatinib(Sprycel) arm in Acute Lymphoblastic Leukemia, Pediatric, sponsored by Hyoung Jin Kang.

Who is sponsoring NCT06257394?

NCT06257394 is sponsored by Hyoung Jin Kang.

What drugs are being tested in NCT06257394?

Interventions in NCT06257394: Dasatinib(Sprycel) arm, Non-Dasatinib(Sprycel) arm.

What condition does NCT06257394 study?

NCT06257394 studies Acute Lymphoblastic Leukemia, Pediatric.

Is NCT06257394 still recruiting?

NCT06257394 is currently recruiting now. Last updated 8 June 2025.

Last reviewed 2025-06-08 · How we verify

NCT06257394: VHR ALL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

Recruiting now Phase 2 Last updated 8 June 2025

What this trial tests

Phase 2 trial testing Dasatinib(Sprycel) arm in Acute Lymphoblastic Leukemia, Pediatric in 74 participants. Currently enrolling.

Timeline

20 October 2024

Primary endpoint
31 December 2034

31 December 2034

Quick facts

Lead sponsor	Hyoung Jin Kang
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	74
Start date	20 October 2024
Primary completion	31 December 2034
Estimated completion	31 December 2034
Sites	6 locations across South Korea

Drugs / interventions tested

Dasatinib(Sprycel) arm — full drug profile →
Non-Dasatinib(Sprycel) arm — full drug profile →

Conditions studied

Acute Lymphoblastic Leukemia, Pediatric — all drugs for Acute Lymphoblastic Leukemia, Pediatric →

Sponsor

Hyoung Jin Kang — full company profile →

Who can join

Adults 1 to 19, any sex, with Acute Lymphoblastic Leukemia, Pediatric. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Very high-risk acute lymphoblastic leukemia

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Molecularly Targeted Small Molecule Inhibitor Therapy for Pediatric Acute Lymphoblastic Leukemia: A Comprehensive Review of Clinical Trials.
Peccatori N, Brivio E, Lissat A, Bautista Sirvent F, et al · · 2025 · PMID 41154380 · DOI 10.3390/cancers17203322

Verify or expand the search:

Other recruiting trials for Acute Lymphoblastic Leukemia, Pediatric

Currently open trials in the same condition.

NCT06559345 — A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Condition · Phase 2 · recruiting
NCT06564493 — A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditionin · Phase 2 · recruiting
NCT06074666 — Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3 · NA · recruiting
NCT06866873 — CD-19 CAR-T Cell for Pediatric ALL or Lymphoma · NA · recruiting
NCT05809284 — Determining the Mechanisms of Loss of CAR T Cell Persistence · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06257394 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hyoung Jin Kang
Last refreshed: 8 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06257394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing